While early efforts to target phosphoinositide-3 kinase (PI3K) involved pan-inhibition, biotechs like Intellikine Inc. and Calistoga Pharmaceuticals Inc. differentiated themselves by selectively targeting the alpha, beta, delta and/or gamma isoforms of PI3K rather than hitting the whole family.
Read More
Currently, FDA approval is pretty much an all-or-nothing deal. Drugs are approved for specific indications, of course. But once a drug is approved, if a patient can find a way to pay for it, with rare exceptions any doctor can prescribe it off-label for any reason.
Read More